AI Summary
✦ ClarthaValuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
5.25
Current
1.52
Overvalued
6.36
Undervalued
2.75
5Y Average
0.76
Current
0.78
Overvalued
0.88
Undervalued
0.65
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Undervalued | -22% vs avg | +10.6% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 22.3x Undervalued | -48% vs avg | +16.6% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Fair | +14% vs avg | +0.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Undervalued | -18% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -13% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -11% vs avg | +31.7% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Fair | -13% vs avg | +29.9% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +111% vs avg | +121.8% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹-0.13 CrMar 2026Latest net profit
₹-4.16 CrMar 2026Latest EPS
₹-0.83Mar 2026Free cash flow
₹0.00 CrMar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 35.32 | 30.56 | 24.30 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.20 | -0.13 |
| Expenses + | 30.98 | 26.51 | 23.25 | 25.60 | 26.81 | 29.04 | 38.60 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 | 1.99 |
| Operating Profit | 4.34 | 4.05 | 1.05 | 1.06 | -3.99 | 1.80 | 0.79 | 0.27 | 3.41 | -0.50 | -4.00 | -0.75 | -2.12 |
| OPM % | 12.29% | 13.25% | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.50% | -130.72% | -34.09% | |
| Other Income + | -18.97 | 0.00 | 0.08 | 0.00 | -8.76 | 0.00 | 1.95 | 8.91 | -21.52 | -20.44 | 0.01 | 0.02 | -0.42 |
| Interest | 0.41 | 0.37 | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 | 0.11 | 0.13 |
| Depreciation | 4.17 | 2.65 | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.80 | 3.90 | 1.57 | 1.57 | 1.57 | 1.31 |
| Profit before tax | -19.21 | 1.03 | -2.11 | -2.06 | -15.97 | -1.86 | -1.31 | 5.91 | -22.12 | -22.54 | -5.68 | -2.41 | -3.98 |
| Tax % | -21.92% | 580.58% | -99.05% | -29.61% | -4.20% | 46.77% | 146.56% | 7.11% | -35.40% | -6.30% | 10.04% | 5.81% | 4.77% |
| Net Profit + | -15.00 | -4.95 | -0.02 | -1.46 | -15.30 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 | -2.55 | -4.16 |
| EPS in Rs | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 | -1.25 | -0.51 | -0.83 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).